Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained prominence during the Coronavirus disease 19 (COVID-19) pandemic. Based on data from three major trials, remdesivir became the first and only medication to obtain approval from the Food and Drug Administration (FDA) to treat patients hospitalized with COVID-19 disease.

Matéria original


Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report


Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2